Opinion ID: 2620291
Heading Depth: 3
Heading Rank: 1

Heading: A method of treating a patient suffering from a

Text: respiratory disease, the method comprising ad- ministering to the patient a nebulized dose of a budesonide composition in a continuing regimen at a frequency of not more than once per day. ’603 Patent col. 10 ll. 18–22. Dependent claims 12, 14, and 16 respectively limit the age range of the patient to “one day to fifteen years old,” “one month to eight years old,” and “six months to five years old.” Id. at col. 10 ll. 44–53. Dependent claims 13, 15 and 17 respectively limit claims 12, 14, and 16 to budesonide compositions in which budesonide is the only active ingredient. Id. at col. 10 ll. 46–55. Dependent claims 24–28 add limitations to claim 1 regarding the amount of budesonide in the budesonide composition. See id. at col. 11 ll. 5 to col. 12 ll. 2. AstraZeneca markets its “once-daily nebulized budesonide suspension used to treat asthma in children” under the name Pulmicort Respules®. Opinion, at .